STOCK TITAN
  1. Home
  2. News
  3. KROS

Keros Therapeutics Inc - KROS STOCK NEWS

Welcome to our dedicated news page for Keros Therapeutics (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Keros Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Keros Therapeutics's position in the market.

News
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
Rhea-AI Summary
Keros Therapeutics, Inc. receives Fast Track designation from the FDA for KER-050 to treat anemia in adult patients with myelodysplastic syndromes. The company plans a Phase 3 clinical trial in the first half of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.18%
Tags
clinical trial
-
News
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
Rhea-AI Summary
Keros Therapeutics, Inc. announces participation in Leerink Partners 2024 Global Biopharma Conference for a fireside chat presentation by CEO Jasbir S. Seehra, Ph.D.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.14%
Tags
conferences
-
News
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Keros Therapeutics, Inc. provided a business update and financial results for Q4 and full year 2023. The company made clinical progress in its pipeline, including Phase 2 trials for KER-012 and KER-050. Keros closed a public offering to strengthen its cash position, expecting funding into 2027. Financially, Keros reported increased net losses due to R&D investments, with revenue from a technology transfer agreement with Hansoh. The company's cash and equivalents stood at $331.1 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
earnings
News
Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress
Rhea-AI Summary
Keros Therapeutics, Inc. announced the presentation of three abstracts from the KER-012 program at the PVRI 2024 Annual Congress. The abstracts focus on the development and administration of KER-012 for the treatment of Pulmonary Arterial Hypertension, showing promising results in preclinical and clinical studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
conferences
-
News
Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock
Rhea-AI Summary
Keros Therapeutics, Inc. (Nasdaq: KROS) closed an underwritten public offering of 4,025,000 shares of common stock at a price of $40.00 per share, resulting in net proceeds of approximately $151.3 million. The company believes that this, together with its cash and cash equivalents, will fund its planned operating expenses and capital expenditure requirements into 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
offering
-
News
Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
Rhea-AI Summary
Keros Therapeutics, Inc. (KROS) announced the pricing of an underwritten public offering of 3,500,000 shares of common stock at a public offering price of $40.00 per share, with expected gross proceeds of $140.0 million. The offering is expected to close on January 8, 2024, and is being made pursuant to a shelf registration statement on Form S-3 filed with the SEC. Goldman Sachs & Co. LLC, Leerink Partners, Piper Sandler, and Truist Securities are acting as joint book-running managers for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.47%
Tags
offering
News
Keros Therapeutics Announces Proposed Public Offering of Common Stock
Rhea-AI Summary
Keros Therapeutics, Inc. (KROS) announces the launch of a proposed underwritten public offering of $120.0 million of shares of its common stock. The offering is subject to market conditions and will be made pursuant to a shelf registration statement on Form S-3 that was filed with the SEC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.47%
Tags
offering
-
News
Keros Therapeutics to Develop KER-065 for the Treatment of Obesity
Rhea-AI Summary
Keros Therapeutics, Inc. (Nasdaq: KROS) announced the commencement of a Phase 1 clinical trial for KER-065, a novel ligand trap designed to treat obesity. The company expects to report initial data in the first quarter of 2025. Preclinical data showed potential proof-of-mechanism for the treatment of obesity, supporting the development of KER-065. Keros plans to initiate a proof-of-concept trial in obese patients following the Phase 1 clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.34%
Tags
none
-
News
Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition
Rhea-AI Summary
Keros Therapeutics, Inc. (Nasdaq: KROS) presented data from its ongoing Phase 2 clinical trials of KER-050, showing durable transfusion independence in lower-risk MDS and potential benefits in myelofibrosis treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.53%
Tags
clinical trial
News
Keros Therapeutics to Present at Upcoming Healthcare Conferences
Rhea-AI Summary
Keros Therapeutics, Inc. announces that its President and CEO will present at two healthcare conferences, providing live audio webcasts and archived replays on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
conferences
Stock KROS logo
Keros Therapeutics Inc

Nasdaq:KROS

KROS Rankings

#1859 Ranked by Market Cap
#4513 Ranked by Stock Gains
N/A Ranked by Dividends

KROS Stock Data

2.11B
30.79M
6.38%
88.88%
5.84%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Lexington

About KROS

keros therapeutics, inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. the company's lead protein therapeutic product candidate is ker-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or mds, and in patients with myelofibrosis. it is also developing small molecule product candidate ker-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or fop, and is currently in a phase 1 clinical trial; and ker-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or pah. the company was founded i